Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Gyre Therapeutics (GYRE) Debt to Equity (2016)

Gyre Therapeutics has reported Debt to Equity over the past 7 years, most recently at $0.0 for Q3 2016.

  • Quarterly Debt to Equity fell 92.35% to $0.0 in Q3 2016 from the year-ago period, while the trailing twelve-month figure was $0.0 through Sep 2016, down 92.35% year-over-year, with the annual reading at $0.04 for FY2015, N/A changed from the prior year.
  • Debt to Equity was $0.0 for Q3 2016 at Gyre Therapeutics, down from $0.01 in the prior quarter.
  • Over five years, Debt to Equity peaked at $0.04 in Q4 2015 and troughed at -$0.02 in Q4 2012.
  • The 5-year median for Debt to Equity is $0.01 (2014), against an average of $0.01.
  • Year-over-year, Debt to Equity plummeted 214.97% in 2012 and then surged 341.03% in 2015.
  • A 5-year view of Debt to Equity shows it stood at -$0.02 in 2012, then surged by 48.19% to -$0.01 in 2013, then soared by 138.39% to $0.0 in 2014, then skyrocketed by 768.93% to $0.04 in 2015, then plummeted by 96.12% to $0.0 in 2016.
  • Per Business Quant, the three most recent readings for GYRE's Debt to Equity are $0.0 (Q3 2016), $0.01 (Q2 2016), and $0.01 (Q1 2016).